Notice of Intent to Sole Source - RPRD Diagnostics

The Centers for Disease Control and Prevention (CDC) intends to award a sole source cost-plus-fixed-fee contract for genetic sequencing to RPRD Diagnostics, Inc. The CDC requires a CLIA-certified or accredited laboratory to test at least 5000 DNA samples using the Axiom PharmacoFocus Array platform as well as long-range PCR and single-molecule sequencing to resolve rare CYP2D6/CYPD2D7 fusion allele genotypes. Only RPRD Diagnostics has both the PharmacoFocus platform and the ability to do both long-range PCR and single molecule sequencing to resolve fusion alleles in a single laboratory. Because the samples come from NHANES, which requires all samples to be tested in a single laboratory, any prospective offeror must be capable of performing all of the work required in a single laboratory.

This notice of intent is not a request for competitive proposals; however, all responses received within fifteen (15) days of the issuance of this notice will be considered by the government for the purpose of whether to conduct a sole source acquisition. A determination by the government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the government. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement. Any response should be emailed to contract specialist William O’Bryan at rvq0@cdc.gov by 5:00 PM EDT on April 27, 2023.